Prestige Consumer Healthcare (NYSE:PBH) Upgraded to "Buy" at StockNews.com

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBH - Free Report) from a hold rating to a buy rating in a research report report published on Tuesday morning.

A number of other equities analysts have also recently issued reports on the company. DA Davidson restated a "buy" rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Raymond James upgraded Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. Jefferies Financial Group restated a "hold" rating and set a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Finally, Sidoti cut Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective for the company. in a report on Monday, December 9th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of "Moderate Buy" and a consensus price target of $85.25.

Prestige Consumer Healthcare Trading Down 0.8 %

Shares of NYSE PBH traded down $0.61 during trading hours on Tuesday, hitting $73.91. 303,061 shares of the company traded hands, compared to its average volume of 317,715. The stock has a market capitalization of $3.65 billion, a price-to-earnings ratio of 17.98, a price-to-earnings-growth ratio of 2.32 and a beta of 0.51. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The company's 50 day moving average price is $80.53 and its 200 day moving average price is $74.14. Prestige Consumer Healthcare has a 12 month low of $58.18 and a 12 month high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $283.79 million for the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company's revenue for the quarter was down .9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS. On average, equities research analysts anticipate that Prestige Consumer Healthcare will post 4.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Adel Mekhail sold 9,063 shares of the business's stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total value of $743,166.00. Following the completion of the transaction, the executive vice president now directly owns 18,365 shares of the company's stock, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider William P'pool sold 8,987 shares of the business's stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the transaction, the insider now directly owns 20,058 shares of the company's stock, valued at approximately $1,641,747.30. The trade was a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,810 shares of company stock worth $3,187,300. 1.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in PBH. Arizona State Retirement System increased its position in Prestige Consumer Healthcare by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 13,900 shares of the company's stock valued at $957,000 after buying an additional 264 shares in the last quarter. Quest Partners LLC increased its position in Prestige Consumer Healthcare by 2,826.7% during the 2nd quarter. Quest Partners LLC now owns 439 shares of the company's stock valued at $30,000 after buying an additional 424 shares in the last quarter. Choreo LLC acquired a new position in shares of Prestige Consumer Healthcare in the second quarter valued at about $677,000. BOKF NA increased its holdings in shares of Prestige Consumer Healthcare by 120.9% in the second quarter. BOKF NA now owns 7,584 shares of the company's stock valued at $522,000 after purchasing an additional 4,150 shares during the period. Finally, GHP Investment Advisors Inc. increased its holdings in shares of Prestige Consumer Healthcare by 1.1% in the second quarter. GHP Investment Advisors Inc. now owns 86,540 shares of the company's stock valued at $5,958,000 after purchasing an additional 928 shares during the period. 99.95% of the stock is owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.